Listed by the USPTO as MARTIN, KEVIN STEPHEN
Tech Center 1600 • Art Units: 1624 1626 1629 1681
This examiner grants 77% of resolved cases
MARTIN, KEVIN STEPHEN is assigned to tech center 1600 and art unit 1624. The profile includes 159 resolved cases, a 77.4% allowance rate, and a 23.3% interview lift. The median time to allowance is 1257 days, which makes prosecution duration an important consideration even with the recorded allowance rate.
Listed companies include Merck Sharp & Dohme LLC, Gilead Sciences Inc., and Alkeus Pharmaceuticals Inc. Listed firms include BALLARD SPAHR LLP, TRASKBRITT, P.C., and ARENTFOX SCHIFF LLP. The interview measure supports considering examiner dialogue as part of a broader prosecution plan.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18255767 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | Final Rejection | The Johns Hopkins University |
| 18694139 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | Non-Final OA | The Regents of the University of California |
| 18570473 | CHIRAL 3-SULFINYL BENZOIC ACIDS | Final Rejection | BAYER AKTIENGESELLSCHAFT |
| 18251111 | CRYSTALLINE FORM IV OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | Final Rejection | LG CHEM, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy77.4% of resolved applications examined by Kevin Stephen Martin were allowed (159 resolved cases), compared with 54.6% across Art Unit 1624 over the last five years.
This examiner's interview lift is +23.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kevin Stephen Martin took 1,257 days on average from filing to allowance.
Kevin Stephen Martin examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
